RU94000061A - Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция - Google Patents

Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция

Info

Publication number
RU94000061A
RU94000061A RU94000061/04A RU94000061A RU94000061A RU 94000061 A RU94000061 A RU 94000061A RU 94000061/04 A RU94000061/04 A RU 94000061/04A RU 94000061 A RU94000061 A RU 94000061A RU 94000061 A RU94000061 A RU 94000061A
Authority
RU
Russia
Prior art keywords
fatty acids
treatment
pharmaceutical
cosmetic composition
unsaturated fatty
Prior art date
Application number
RU94000061/04A
Other languages
English (en)
Other versions
RU2142468C1 (ru
Inventor
Фредерик Хорробин Дэвид
Original Assignee
Скотиа Холдингс ПЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939300125A external-priority patent/GB9300125D0/en
Application filed by Скотиа Холдингс ПЛС filed Critical Скотиа Холдингс ПЛС
Publication of RU94000061A publication Critical patent/RU94000061A/ru
Application granted granted Critical
Publication of RU2142468C1 publication Critical patent/RU2142468C1/ru

Links

Claims (1)

  1. Эфиры холестерина и жирных кислот, в которых жирные кислоты выбраны из существующих жирных кислот или из паринаровой или колумбиновой кислоты. Последние могут использоваться в терапии, особенно при лечении рака и сердечно-сосудистых заболеваний.
RU94000061A 1993-01-06 1994-01-05 Эфиры холестерина и жирной кислоты, способ лечения и фармацевтическая или косметическая композиция RU2142468C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939300125A GB9300125D0 (en) 1993-01-06 1993-01-06 Compositions containing esters of unsaturated fatty acids
GB9300125.3 1993-01-06

Publications (2)

Publication Number Publication Date
RU94000061A true RU94000061A (ru) 1995-08-27
RU2142468C1 RU2142468C1 (ru) 1999-12-10

Family

ID=10728334

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94000061A RU2142468C1 (ru) 1993-01-06 1994-01-05 Эфиры холестерина и жирной кислоты, способ лечения и фармацевтическая или косметическая композиция

Country Status (17)

Country Link
US (1) US5604216A (ru)
EP (1) EP0606012B1 (ru)
JP (1) JPH06234644A (ru)
KR (1) KR940018088A (ru)
CN (1) CN1096197A (ru)
AT (1) ATE168267T1 (ru)
AU (1) AU673555B2 (ru)
CA (1) CA2112824A1 (ru)
DE (1) DE69319710T2 (ru)
DK (1) DK0606012T3 (ru)
ES (1) ES2119871T3 (ru)
GB (1) GB9300125D0 (ru)
MY (1) MY110765A (ru)
NO (1) NO940035D0 (ru)
NZ (1) NZ250583A (ru)
RU (1) RU2142468C1 (ru)
ZA (1) ZA9425B (ru)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US5892068A (en) * 1998-08-25 1999-04-06 Mcneil-Ppc, Inc. Preparation of sterol and stanol-esters
NZ333817A (en) * 1998-08-25 2000-09-29 Mcneil Ppc Inc Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
DE60028368T2 (de) * 1999-04-15 2007-02-01 Kaneka Corp. Agonisten des peroxisom aktivator-responsiven rezeptors
US6998501B1 (en) * 1999-08-30 2006-02-14 Ocean Nutrition Canada Limited Nutritional supplement for lowering serum triglyceride and cholesterol levels
EP1211955A1 (en) * 1999-08-30 2002-06-12 Ocean Nutrition Canada Ltd. A nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
ATE384518T1 (de) * 2000-01-31 2008-02-15 Haerting S A Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
KR20010091499A (ko) * 2000-03-16 2001-10-23 김용범 레이저 그래픽 디스플레이 장치
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
JP2003048831A (ja) * 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
WO2004068970A2 (en) * 2003-01-31 2004-08-19 The Procter & Gamble Company Means for improving the appearance of mammalian keratinous tissue
WO2004112777A1 (ja) * 2003-06-20 2004-12-29 Mochida Pharmaceutical Co., Ltd. 下肢静脈瘤予防・治療用組成物
CA2436650A1 (en) * 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
US20060141046A1 (en) * 2004-05-06 2006-06-29 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
JP2007536259A (ja) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド 活性薬剤の送達のための粒子
CN103211807A (zh) * 2005-07-08 2013-07-24 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
US20080110624A1 (en) * 2005-07-15 2008-05-15 Halliburton Energy Services, Inc. Methods for controlling water and particulate production in subterranean wells
ITMI20052377A1 (it) * 2005-12-13 2007-06-14 Anna Petroni Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP3578177A1 (en) 2008-09-02 2019-12-11 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
KR20140007973A (ko) 2009-02-10 2014-01-20 아마린 파마, 인크. 고중성지방혈증 치료 방법
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
BRPI1011876B1 (pt) 2009-04-29 2020-03-31 Amarin Pharma, Inc. Composições farmacêuticas estáveis compreendendo etilácido eicosapentaenoico (etil-epa) e uso das mesmas para tratar ou prevenir uma doença relacionada ao cardiovascular
CN102625847A (zh) 2009-06-15 2012-08-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2495242B1 (en) * 2009-10-29 2016-05-04 Industry-Academic Cooperation Foundation Yonsei University Novel vascular leak inhibitor
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
SG10201913645RA (en) 2012-06-29 2020-03-30 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
ES2924084T3 (es) * 2012-10-11 2022-10-04 Chem Cure Ass Llc Composición tópica para su uso en el tratamiento de la psoriasis
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6224203B2 (ja) * 2016-12-08 2017-11-01 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するための組成物
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP6491293B2 (ja) * 2017-10-04 2019-03-27 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51765A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
JP6728425B2 (ja) * 2019-02-28 2020-07-22 アナプラシ ファーマシューティカルズ エルエルシー 乾癬を治療するためのクリーム、ローション、又はゲルの組成物
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Similar Documents

Publication Publication Date Title
RU94000061A (ru) Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
GB9300125D0 (en) Compositions containing esters of unsaturated fatty acids
CA2144312A1 (en) Unsaturated aliphatic dicarboxylic acids
EP0808324A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CARDIOVASCULAR DISEASES
AU2080988A (en) Esters of 13-trans-retinoic acid
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
NO940277L (no) Triglycerider og blandinger av slike
CA2195213A1 (en) Use of droloxifene for the treatment of cardiovascular diseases
NL7904144A (nl) Vetzuurpreparaten ter behandeling en voorkomen van thrombo-embolie.
CA2289717A1 (en) Novel therapy for constipation
ITRM930356A0 (it) Uso di esteri sull'ossidrile della l-carnitina per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
ITRM930399A0 (it) Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
DE59504267D1 (de) Härten von ungesättigten fetten, fettsäuren oder fettsäureestern
DE3851941D1 (de) Polycyclische aromatische Ester von makroliden Antibiotika und linkosamiden Antibiotika, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen und kosmetischen Zusammensetzungen.
ITRM930365A0 (it) Uso di esteri sull'ossidrile della l-carnitina con acidi aromatici perprodurre composizioni farmaceutiche per il trattamento di affezioni cutanee.
IL85776A (en) Pharmaceutical compositions comprising certain selenium containing algae and c18-c22 unsaturated acids and their preparation,used for treating conditions of the heart and cardiovascular system
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
ATE113291T1 (de) Polyaromatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
AU6724890A (en) Method for the preparation of fat mixtures comprising eicosapentaenoate ester from worms of family lumbricidae and, optionally fatty acid mixtures comprising eicosapentaenoic acid therefrom
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
ES2191825T3 (es) Sales metalicas de acidos biliares con accion fisiologica y su uso en terapia.
ATE113290T1 (de) Nicht gesättigte cycloaliphatische ester von makroliden antibiotika und linkosamiden antibiotika, verfahren zu ihrer herstellung und die sie enthaltenden pharmazeutischen und kosmetischen zusammensetzungen.
DE69600338D1 (de) Verfahren zur Herstellung von Naphthalin-2,6-dicarbonsäure und ihrem Ester
EP0792878A3 (en) Geminal carboxylic acids and esters thereof, pharmaceutical formulations containing them useful in the treatment of bone dysmetabolism